NYSE · VRTX
Healthcare · Biotechnology
$502.31
Up+$3.33 (+0.66%)
Updated Oct 7, 2026, 8:46 PM
SID Score
6.1/10
Composite research score
Smart Money
52/100
Neutral
Price performance · VRTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
VRTX closed at $502.31 after 21 trading sessions, down 5.03% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $505.00 | $507.41 | $496.325 | $502.31 | 775.07K |
| Oct 5, 2026 | $504.78 | $506.01 | $496.15 | $503.50 | 915.14K |
| Oct 2, 2026 | $509.50 | $509.50 | $499.95 | $504.73 | 939.66K |
| Oct 1, 2026 | $522.39 | $523.515 | $505.27 | $506.74 | 1.19M |
| Sep 30, 2026 | $525.26 | $529.72 | $522.74 | $522.81 | 1.15M |
| Sep 29, 2026 | $522.22 | $529.46 | $519.245 | $526.73 | 688.93K |
| Sep 28, 2026 | $524.27 | $529.89 | $521.16 | $527.67 | 824.74K |
| Sep 25, 2026 | $522.55 | $527.69 | $518.92 | $526.19 | 756.21K |
| Sep 24, 2026 | $515.56 | $528.99 | $515.30 | $522.38 | 941.06K |
| Sep 23, 2026 | $515.60 | $525.4296 | $509.56 | $516.34 | 1.21M |
| Sep 22, 2026 | $521.69 | $525.97 | $508.1426 | $514.99 | 1.39M |
| Sep 21, 2026 | $506.85 | $514.10 | $501.01 | $510.72 | 906.68K |
| Sep 18, 2026 | $516.34 | $518.10 | $505.01 | $508.34 | 2.43M |
| Sep 17, 2026 | $518.35 | $519.07 | $510.195 | $516.34 | 900.05K |
| Sep 16, 2026 | $513.80 | $517.95 | $511.35 | $513.26 | 638.51K |
| Sep 15, 2026 | $519.94 | $519.94 | $511.001 | $514.63 | 824.89K |
| Sep 14, 2026 | $522.17 | $525.29 | $514.655 | $519.51 | 837.11K |
| Sep 11, 2026 | $522.10 | $522.10 | $511.81 | $515.44 | 875.64K |
| Sep 10, 2026 | $519.13 | $522.60 | $514.32 | $514.56 | 815.17K |
| Sep 9, 2026 | $524.00 | $528.165 | $520.08 | $521.12 | 958.51K |
| Sep 8, 2026 | $529.64 | $535.00 | $520.20 | $528.90 | 1.12M |
The latest Smart Investors Daily articles mentioning VRTX.
Company
Market Activity
Research & News
VRTX research
Company profile and research snapshot.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | UBS | Buy | — |
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 2, 2026 | Morgan Stanley | Overweight | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
| Aug 5, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 3, 2026
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]
Yahoo · Oct 1, 2026
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
Yahoo · Oct 1, 2026
VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") is pleased to announce that, further to its news release dated September 17, 2026, it has completed the acquisition (the “Acquisition”) of the Purchased Assets (as defined below) comprising the Meadows Project located in west-central Saskatchewan near the Alberta border (the "Meadows Project"). The Meadows Project is represented by Saskatchewan Subsur
Benzinga · Sep 29, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals has a market
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VRTX.
